Cancer stem cells in cutaneous melanoma

References

• Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med.355(1), 51–65 (2006).
   PubMed Web of Science ®Google Scholar
• Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol. Appl. Skin Physiol.14(5), 280–290 (2001).
   PubMedGoogle Scholar
• Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations – US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch. Dermatol.141(4), 477–481 (2005).
   PubMed Web of Science ®Google Scholar
• Chang YM, Barrett JH, Bishop DT et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int. J. Epidemiol. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Cancer Facts and Figures 2008. American Cancer Society, Atlanta, GA, USA (2008).
   Google Scholar
• Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol.150(2), 179–185 (2004).
   PubMed Web of Science ®Google Scholar
• Schaffer JV, Rigel DS, Kopf AW, Bolognia JL. Cutaneous melanoma – past, present, and future. J. Am. Acad. Dermatol.51(1 Suppl.), S65–S69 (2004).
   Google Scholar
• Wang SQ, Halpern AC. Management of cutaneous melanoma: a public health and individual patient care perspective. Adv. Dermatol.23, 81–98 (2007).
   PubMedGoogle Scholar
• Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr. Probl. Surg.42(7), 460–534 (2005).
   PubMedGoogle Scholar
• Buzaid AC. Management of metastatic cutaneous melanoma. Oncology (Williston Park)18(11), 1443–1450; discussion 1457–1449 (2004).
   PubMed Web of Science ®Google Scholar
• Agar N, Young AR. Melanogenesis: a photoprotective response to DNA damage?. Mutat. Res.571(1–2), 121–132 (2005).
   PubMed Web of Science ®Google Scholar
• Meredith P, Riesz J. Radiative relaxation quantum yields for synthetic eumelanin. Photochem. Photobiol.79(2), 211–216 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem. Photobiol.84(3), 539–549 (2008).
   PubMed Web of Science ®Google Scholar
• Kavak A, Akcan Y, Korkmaz U. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin. Dermatology211(2), 171–172 (2005).
   PubMedGoogle Scholar
• Na GY, Paek SH, Park BC et al. Isolation and characterization of outer root sheath melanocytes of human hair follicles. Br. J. Dermatol.155(5), 902–909 (2006).
   PubMed Web of Science ®Google Scholar
• Moriyama M, Osawa M, Mak SS et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J. Cell Biol.173(3), 333–339 (2006).
   PubMed Web of Science ®Google Scholar
• Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med.12(9), 406–414 (2006).
   PubMed Web of Science ®Google Scholar
• Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem. Biophys. Res. Commun.354(3), 830–835 (2007).
   PubMed Web of Science ®Google Scholar
• Murisier F, Guichard S, Beermann F. The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. Pigment Cell Res.20(3), 173–184 (2007).
   PubMedGoogle Scholar
• Wegner M. Secrets to a healthy Sox life: lessons for melanocytes. Pigment Cell Res.18(2), 74–85 (2005).
   PubMedGoogle Scholar
• Lang D, Epstein JA. Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. Hum. Mol. Genet.12(8), 937–945 (2003).
   PubMed Web of Science ®Google Scholar
• Lang D, Lu MM, Huang L et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature433(7028), 884–887 (2005).
   PubMed Web of Science ®Google Scholar
• Yang G, Li Y, Nishimura EK et al. Inhibition of PAX3 by TGF-β modulates melanocyte viability. Mol. Cell32(4), 554–563 (2008).
   PubMed Web of Science ®Google Scholar
• Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D. Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res.21(6), 627–645 (2008).
   PubMed Web of Science ®Google Scholar
• Nishikawa S, Osawa M. Generating quiescent stem cells. Pigment Cell Res.20(4), 263–270 (2007).
   PubMedGoogle Scholar
• Osawa M, Egawa G, Mak SS et al. Molecular characterization of melanocyte stem cells in their niche. Development132(24), 5589–5599 (2005).
   PubMed Web of Science ®Google Scholar
• Morris RJ, Liu Y, Marles L et al. Capturing and profiling adult hair follicle stem cells. Nat. Biotechnol.22(4), 411–417 (2004).
   PubMed Web of Science ®Google Scholar
• Tumbar T, Guasch G, Greco V et al. Defining the epithelial stem cell niche in skin. Science303(5656), 359–363 (2004).
   PubMed Web of Science ®Google Scholar
• Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res.17(4), 318–325 (2004).
   PubMedGoogle Scholar
• Garraway LA, Widlund HR, Rubin MA et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature436(7047), 117–122 (2005).
   PubMed Web of Science ®Google Scholar
• Carreira S, Goodall J, Denat L et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev.20(24), 3426–3439 (2006).
   PubMed Web of Science ®Google Scholar
• Larue L, Delmas V. The WNT/B-catenin pathway in melanoma. Front Biosci.11, 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Lin YC, You L, Xu Z et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum. Gene Ther.18(4), 379–386 (2007).
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lee CS, Scolyer RA et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol.20(4), 416–426 (2007).
   PubMed Web of Science ®Google Scholar
• Weeraratna AT. A Wnt-er wonderland – the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev.24(2), 237–250 (2005).
   PubMedGoogle Scholar
• Wellbrock C, Rana S, Paterson H et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE3(7), e2734 (2008).
   PubMed Web of Science ®Google Scholar
• Malanchi I, Peinado H, Kassen D et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature452(7187), 650–653 (2008).
   PubMed Web of Science ®Google Scholar
• Watt FM, Collins CA. Role of β-catenin in epidermal stem cell expansion, lineage selection, and cancer. Cold Spring Harb. Symp. Quant. Biol. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett.279(1), 8–12 (2008).
   PubMedGoogle Scholar
• Chien AJ, Moore EC, Lonsdorf AS et al. Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA106(4), 1193–1198 (2009).
   PubMed Web of Science ®Google Scholar
• Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature456(7222), 593–598 (2008).
   PubMed Web of Science ®Google Scholar
• Dick JE. Looking ahead in cancer stem cell research. Nat. Biotechnol.27(1), 44–46 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells – perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res.66(19), 9339–9344 (2006).
   PubMedGoogle Scholar
• Eaves CJ. Cancer stem cells: here, there, everywhere?. Nature456(7222), 581–582 (2008).
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Doukaki S, Malleo F, Arico M. Identification of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol. Ther.21(Suppl. 1), S1–S5 (2008).
   PubMedGoogle Scholar
• Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Res.66(4), 1883–1890 (2006).
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med.3, 730–737 (1997).
   PubMed Web of Science ®Google Scholar
• Wright MH, Calcagno AM, Salcido CD et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res.10(1), R10 (2008).
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature445(7123), 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Ohkuma M, Sakashita H et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol.15(10), 2927–2933 (2008).
   PubMed Web of Science ®Google Scholar
• Vander Griend DJ, Karthaus WL, Dalrymple S et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res.68(23), 9703–9711 (2008).
   PubMedGoogle Scholar
• Kelly K, Yin JJ. Prostate cancer and metastasis initiating stem cells. Cell Res.18(5), 528–537 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res.68(11), 4311–4320 (2008).
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res.67(3), 1030–1037 (2007).
   PubMed Web of Science ®Google Scholar
• Kiel MJ, He S, Ashkenazi R et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature449(7159), 238–242 (2007).
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res.65(20), 9328–9337 (2005).
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res.65(10), 4320–4333 (2005).
   PubMed Web of Science ®Google Scholar
• Grichnik JM, Burch JA, Schulteis RD et al. Melanoma, a tumor based on a mutant stem cell?. J. Invest. Dermatol.126(1), 142–153 (2006).
   PubMed Web of Science ®Google Scholar
• Klein WM, Wu BP, Zhao S et al. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol.20(1), 102–107 (2007).
   PubMed Web of Science ®Google Scholar
• Monzani E, Facchetti F, Galmozzi E et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer43(5), 935–946 (2007).
   PubMed Web of Science ®Google Scholar
• Mihic-Probst D, Kuster A, Kilgus S et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer121(8), 1764–1770 (2007).
   PubMedGoogle Scholar
• Sigalotti L, Covre A, Zabierowski S et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell. Physiol.215(2), 287–291 (2008).
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature451(7176), 345–349 (2008).
   PubMed Web of Science ®Google Scholar
• Keshet GI, Goldstein I, Itzhaki O et al. MDR1 expression identifies human melanoma stem cells. Biochem. Biophys. Res. Commun.368(4), 930–936 (2008).
   PubMedGoogle Scholar
• Cook AL, Donatien PD, Smith AG et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J. Invest. Dermatol.121(5), 1150–1159 (2003).
   PubMedGoogle Scholar
• Strizzi L, Abbott DE, Salomon DS, Hendrix MJ. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle7(13), 1931–1935 (2008).
   PubMed Web of Science ®Google Scholar
• Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol.15(5), 378–386 (2005).
   PubMed Web of Science ®Google Scholar
• Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell13(3), 185–187 (2008).
   PubMedGoogle Scholar
• Zhou J, Wang CY, Liu T et al. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol.14(6), 925–930 (2008).
   PubMed Web of Science ®Google Scholar
• Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia14(1), 3–9 (2009).
   PubMed Web of Science ®Google Scholar
• Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev.61(1), 26–33 (2009).
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun T, Schneider-Broussard R et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res.65(14), 6207–6219 (2005).
   PubMed Web of Science ®Google Scholar
• Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev.26(1), 39–57 (2007).
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA101(39), 14228–14233 (2004).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Brafford P, Haass NK et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am. J. Pathol.166(5), 1541–1554 (2005).
   PubMedGoogle Scholar
• Feldmann G, Dhara S, Fendrich V et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res.67(5), 2187–2196 (2007).
   PubMed Web of Science ®Google Scholar
• Balint K, Xiao M, Pinnix CC et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J. Clin. Invest.115(11), 3166–3176 (2005).
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Xiao M, Balint K et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res.66(8), 4182–4190 (2006).
   PubMed Web of Science ®Google Scholar
• Stecca B, Mas C, Clement V et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl Acad. Sci. USA104(14), 5895–5900 (2007).
   PubMed Web of Science ®Google Scholar
• Qin JZ, Stennett L, Bacon P et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol. Cancer Ther.3(8), 895–902 (2004).
   PubMed Web of Science ®Google Scholar
• Hamai A, Meslin F, Benlalam H et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res.68(23), 9854–9864 (2008).
   PubMedGoogle Scholar
• Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells26(12), 3008–3017 (2008).
   PubMed Web of Science ®Google Scholar
• Yi JM, Tsai HC, Glockner SC et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res.68(19), 8094–8103 (2008).
   PubMed Web of Science ®Google Scholar
• Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res.68(19), 7882–7886 (2008).
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst.98(7), 472–482 (2006).
   PubMedGoogle Scholar
• Kauffmann A, Rosselli F, Lazar V et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene27(5), 565–573 (2008).
   PubMedGoogle Scholar